Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

The Public Health Agency of Canada is part of the federal health portfolio. Our activities focus on protecting against threats to public health, preventing and reducing diseases and injury, and ...

Amicus Therapeutics announced that it will showcase two oral presentations and 20 posters related to its research on Fabry and Pompe diseases at the 21st Annual WORLDSymposium™ 2025 taking place ...

ABU DHABI, 13th June, 2017 (WAM) -- The Ministry of Health and Prevention has signed an agreement with Pfizer-Gulf to raise local community awareness on infectious diseases and highlight the role of ...

a sickle cell disease (“SCD”) therapy, serves as a cautionary tale. After paying >$5.5bn to acquire Global Blood Therpeutics and its lead commercial drug Oxbryta, Pfizer has had to withdraw ...

which have the potential to help address the diverse needs of patients across various stages of disease.” Pfizer’s GU portfolio includes seven approved medicines across bladder, prostate ...

NEW YORK, January 28, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE ... the diverse needs of patients across various stages of disease." ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...